IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科
学科主题临床医学
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells
Qiu, Hong1,3; Yashiro, Masakazu1,2; Zhang, Xiaotian1,4; Miwa, Atsushi5; Hirakawa, Kosei1
关键词FGFR2 inhibitor Drug resistance Gastric cancer Combination therapy Chemosensitivity
刊名CANCER LETTERS
2011-08-01
DOI10.1016/j.canlet.2011.03.015
307期:1页:47-52
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者KAKENHI ; Japan-China Sasagawa Medical Scholarship ; KAKENHI ; Japan-China Sasagawa Medical Scholarship
研究领域[WOS]Oncology
关键词[WOS]CISPLATIN-BASED CHEMOTHERAPY ; LUNG-CANCER ; PHASE-II ; FOLINIC ACID ; 5-FLUOROURACIL ; CARCINOMA ; COMBINATION ; EXPRESSION ; REPAIR ; LINES
英文摘要

Aim: The aim of this study was to clarify the ability of a FGFR2 inhibitor, Ki23057, to enhance the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs.

Materials and methods: Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM. The effects of the combination of Ki23057 with anticancer drugs on proliferation, apoptosis, and mRNA expression were examined.

Results: Ki23057 significantly decreased the IC(50) values of OCUM-2M/SN38, OCUM-2M/PTX, and OCUM-2M/VP16, but not those of OCUM-2M/OXA and OCUM-2M/GEM. Ki23057 significantly enhanced the apoptosis rates induced by chemotherapeutic drugs in both the drug-resistant cell lines and the parental cell line. Ki23057 decreased the ERCC1 expression level in OCUM-2M/SN38, OCUM-2M/PTX, and OCUM-2M/VP16. Ki23057 increased the p53 expression level in OCUM-2M/SN38 and OCUM-2M/PTX, but not in OCUM-2M/VP16.

Conclusion: The FGFR2 inhibitor Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism between Ki23057 and chemotherapeutic agents in drug-resistant cell lines. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

语种英语
所属项目编号22390262 ; 20591573
资助者KAKENHI ; Japan-China Sasagawa Medical Scholarship ; KAKENHI ; Japan-China Sasagawa Medical Scholarship
WOS记录号WOS:000292179200006
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66987
专题北京大学临床肿瘤学院_肿瘤内科
作者单位1.Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 5458585, Japan
2.Osaka City Univ, Grad Sch Med, Oncol Inst Geriatr & Med Sci, Abeno Ku, Osaka 5458585, Japan
3.Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Ctr Oncol, Wuhan 430074, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Med Oncol, Beijing 100871, Peoples R China
5.Kyowa Hakko Kirin Co Ltd, Drug Discovery Res Labs, Shizuoka, Japan
推荐引用方式
GB/T 7714
Qiu, Hong,Yashiro, Masakazu,Zhang, Xiaotian,et al. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells[J]. CANCER LETTERS,2011,307(1):47-52.
APA Qiu, Hong,Yashiro, Masakazu,Zhang, Xiaotian,Miwa, Atsushi,&Hirakawa, Kosei.(2011).A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.CANCER LETTERS,307(1),47-52.
MLA Qiu, Hong,et al."A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells".CANCER LETTERS 307.1(2011):47-52.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qiu, Hong]的文章
[Yashiro, Masakazu]的文章
[Zhang, Xiaotian]的文章
百度学术
百度学术中相似的文章
[Qiu, Hong]的文章
[Yashiro, Masakazu]的文章
[Zhang, Xiaotian]的文章
必应学术
必应学术中相似的文章
[Qiu, Hong]的文章
[Yashiro, Masakazu]的文章
[Zhang, Xiaotian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。